Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin

被引：0
作者：
Miners, John O. [1 ]
Pattanawongsa, Attarat [1 ]
Rowland, Andrew [1 ]
机构：
[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Dept Clin Pharmacol, GPO Box 2100, Adelaide, SA 5001, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2018年 / 84卷 / 02期
关键词：
canagliflozin; drug-drug interaction; enzyme inhibition; UDP-glucuronosyltransferase; UDP-GLUCURONOSYLTRANSFERASE ENZYMES; GLUCURONIDATION; PHARMACOLOGY; INHIBITION; GUIDE;
D O I：
10.1111/bcp.13443
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：392 / 393
页数：2
相关论文
共 7 条
  • [1] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Enzymes
    Alexander, Stephen P. H.
    Fabbro, Doriano
    Kelly, Eamonn
    Marrion, Neil
    Peters, John A.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Southan, Christopher
    Davies, Jamie A.
    Aldrich, R.
    Attali, B.
    Back, M.
    Barnes, N. M.
    Bathgate, R.
    Beart, P. M.
    Becirovic, E.
    Biel, M.
    Birdsall, N. J.
    Boison, D.
    Brauner-Osborne, H.
    Broeer, S.
    Bryant, C.
    Burnstock, G.
    Burris, T.
    Cain, D.
    Calo, G.
    Chan, S. L.
    Chandy, K. G.
    Chiang, N.
    Christakos, S.
    Christopoulos, A.
    Chun, J. J.
    Chung, J. -J.
    Clapham, D. E.
    Connor, M. A.
    Coons, L.
    Cox, H. M.
    Dautzenberg, F. M.
    Dent, G.
    Douglas, S. D.
    Dubocovich, M. L.
    Edwards, D. P.
    Farndale, R.
    Fong, T. M.
    Forrest, D.
    Fowler, C. J.
    Fuller, P.
    Gainetdinov, R. R.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) : 6024 - 6109
  • [2] In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin
    Mamidi, Rao N. V. S.
    Dallas, Shannon
    Sensenhauser, Carlo
    Lim, Heng Keang
    Scheers, Ellen
    Verboven, Peter
    Cuyckens, Filip
    Leclercq, Laurent
    Evans, David C.
    Kelley, Michael F.
    Johnson, Mark D.
    Snoeys, Jan
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 1082 - 1096
  • [3] Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
    Miners, John O.
    Chau, Nuy
    Rowland, Andrew
    Burns, Kushari
    McKinnon, Ross A.
    Mackenzie, Peter I.
    Tucker, Geoffrey T.
    Knights, Kathleen M.
    Kichenadasse, Ganessan
    [J]. BIOCHEMICAL PHARMACOLOGY, 2017, 129 : 85 - 95
  • [4] The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential
    Miners, John O.
    Mackenzie, Peter I.
    Knights, Kathleen M.
    [J]. DRUG METABOLISM REVIEWS, 2010, 42 (01) : 196 - 208
  • [5] Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions
    Pattanawongsa, Attarat
    Chau, Nuy
    Rowland, Andrew
    Miners, John O.
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) : 1468 - 1476
  • [6] The "Albumin Effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities
    Rowland, Andrew
    Knights, Kathleen M.
    Mackenzie, Peter I.
    Miners, John O.
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (06) : 1056 - 1062
  • [7] The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
    Southan, Christopher
    Sharman, Joanna L.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Alexander, Stephen P. H.
    Buneman, O. Peter
    Davenport, Anthony P.
    McGrath, John C.
    Peters, John A.
    Spedding, Michael
    Catterall, William A.
    Fabbro, Doriano
    Davies, Jamie A.
    [J]. NUCLEIC ACIDS RESEARCH, 2016, 44 (D1) : D1054 - D1068
1